Drugs Monitor, Page 4

(01 May 2021) Favipiravir- found to be superior in shortening the duration of viral shedding

May 24, 2021

Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial https://doi.org/10.1016/j.intimp.2021.107702 NCT04333589- Between March 27 and May 9, 2020, 55 patients underwent randomization; 36 were assigned to the favipiravir group and 19… Continue reading "(01 May 2021) Favipiravir- found to be superior in shortening the duration of viral shedding"

(29 Apr 2021) Chloroquine/Hydroxychloroquine- resulted in a significant worsening of clinical status

April 30, 2021

An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients https://doi.org/10.1038/s41598-021-88509-9 NCT04420247-This randomized, open-label, controlled, phase III trial assessed the efficacy of chloroquine or hydroxychloroquine for five days in combination with standard care compared to standard… Continue reading "(29 Apr 2021) Chloroquine/Hydroxychloroquine- resulted in a significant worsening of clinical status"

(28 Apr 2021) Camostat mesilate- did not affect time to clinical improvement

April 30, 2021

Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial https://doi.org/10.1016/j.eclinm.2021.100849 NCT04321096- 137 patients were assigned to receive camostat mesilate and 68 to placebo. Median time to clinical improvement was 5 days (interquartile range… Continue reading "(28 Apr 2021) Camostat mesilate- did not affect time to clinical improvement"

(27 Apr 2021) Azithromycin- adding AZT to SOC did not reduce the risk of hospitalization or death

April 30, 2021

A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial https://www.medrxiv.org/content/10.1101/2021.04.21.21255807v1 NCT04381962- 298 participants were enrolled from 3rd June 2020 to 29th January 2021. The primary outcome was assessed in 292 participants. The primary endpoint… Continue reading "(27 Apr 2021) Azithromycin- adding AZT to SOC did not reduce the risk of hospitalization or death"

(25 Apr 2021) Dexamethasone- showed better survival in severe COVID-19 compared to TCZ

April 30, 2021

Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab https://doi.org/10.1038/s41598-021-88086-x 109 critically ill COVID-19 patients randomly assigned to either TCZ therapy (46 patients) or pulse Dexamethasone therapy (63 patients). Kaplan-Meier survival… Continue reading "(25 Apr 2021) Dexamethasone- showed better survival in severe COVID-19 compared to TCZ"

(24 Apr 2021) Favipiravir- was associated with accelerated discharge rate

April 30, 2021

Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: A retrospective study with propensity score matching sensitivity analysis https://doi.org/10.1080/03007995.2021.1920900 Overall, median time to discharge was 10 days (95%CI =9-10) in the favipiravir arm… Continue reading "(24 Apr 2021) Favipiravir- was associated with accelerated discharge rate"

(23 Apr 2021) Hydroxychloroquine, Lopinavi/R- no significant benefit for decreasing COVID-19-associated hospitalization

April 30, 2021

Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial https://doi.org/10.1001/jamanetworkopen.2021.6468 NCT04403100- Of 685 participants, 632 (92.3%) self-identified as mixed-race, 377 (55.0%) were women, and the median… Continue reading "(23 Apr 2021) Hydroxychloroquine, Lopinavi/R- no significant benefit for decreasing COVID-19-associated hospitalization"

(20 Apr 2021) EpAbs (INM005)- mortality was 69% the INM005 group Vs 114% in the placebo

April 30, 2021

RBD-specific polyclonal F(ab )2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial https://doi.org/10.1016/j.eclinm.2021.100843 NCT04494984-Enrolled patients were assigned to receive two blinded doses of INM005 (n =… Continue reading "(20 Apr 2021) EpAbs (INM005)- mortality was 6*9% the INM005 group Vs 11*4% in the placebo"

(20 Apr 2021) Ruxolitinib- may be an alternative anti-cytokine therapy

April 30, 2021

Ruxolitinib versus Dexamethasone in Hospitalized Adults with Covid-19: multicenter matched-controlled study https://www.medrxiv.org/content/10.1101/2021.04.20.21255662v1 NCT04337359-Ruxolitinib treatment in the general cohort of patients was associated with equivalent to dexamethasone mortality rate: 9,6% (95% CI 4,6-14,6%) vs 13,0% (95% CI 7,5-18,5%, superiority p=0.35, non-inferiority… Continue reading "(20 Apr 2021) Ruxolitinib- may be an alternative anti-cytokine therapy"

(20 Apr 2021) Nitazoxanide- was associated with an 85% reduction in the progression to severe illness

April 30, 2021

Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization https://www.medrxiv.org/content/10.1101/2021.04.19.21255441v1 NCT04486313- Time to sustained response was not reduced by nitazoxanide (median: 13.28 and 12.35 days for nitazoxanide and placebo). Nitazoxanide treatment provided an 85% reduction… Continue reading "(20 Apr 2021) Nitazoxanide- was associated with an 85% reduction in the progression to severe illness"